Tirzepatide and semaglutide are the two biggest names in metabolic medicine, and the question people ask most is simple: which one is better? The honest answer is that they are closely related but not identical — tirzepatide hits one extra receptor, and in head-to-head testing that has translated into larger average results. Here is how they actually compare.
For the full mechanism of each, see tirzepatide's mechanism of action and how semaglutide works.
Quick Comparison
| Tirzepatide | Semaglutide | |
|---|---|---|
| Brands | Mounjaro, Zepbound | Ozempic, Wegovy, Rybelsus |
| Receptors | GIP + GLP-1 (dual) | GLP-1 only |
| Maker | Eli Lilly | Novo Nordisk |
| Forms | Weekly injection | Weekly injection; daily and oral pill options |
| Avg. weight loss (obesity trials) | ~15–21% (SURMOUNT) | ~15% (STEP, 2.4 mg) |
| Head-to-head (diabetes) | Greater A1c and weight reduction | Comparator in SURPASS-2 |
The Core Difference: One Receptor vs Two
Semaglutide is a GLP-1 receptor agonist — it activates a single incretin receptor. Tirzepatide is a dual agonist that activates both the GLP-1 receptor and the GIP receptor. Both pathways increase glucose-dependent insulin release, suppress glucagon, slow gastric emptying and reduce appetite; the GIP component in tirzepatide adds effects on fat-tissue metabolism and may improve tolerability. That extra receptor is the single biggest reason the two drugs behave differently.
Head-to-Head Evidence
The clearest comparison comes from SURPASS-2, a randomized trial that pitted tirzepatide directly against semaglutide in people with type 2 diabetes. Across its doses, tirzepatide produced greater reductions in both A1c and body weight. In obesity, there is no single head-to-head trial, but across their separate programs tirzepatide's SURMOUNT trials reported average weight loss in the 15–21% range at higher doses, versus roughly 15% for semaglutide's 2.4 mg dose in STEP. The general pattern: tirzepatide tends to produce larger average results, though individual response varies and both are highly effective.
Forms and Convenience
Semaglutide has more delivery options: a weekly injection (Ozempic, Wegovy), a daily oral tablet (Rybelsus), and a newer oral Wegovy pill for weight management. Tirzepatide is currently a weekly injection only. For people who strongly prefer a pill, that flexibility can matter more than a few percentage points of average weight loss.
Side Effects
Both share the same profile, driven by their shared GLP-1 action: gastrointestinal effects (nausea, diarrhea, vomiting, constipation) that are worst during dose escalation. Both carry a boxed warning for thyroid C-cell tumors and are avoided in people with a history of medullary thyroid carcinoma or MEN 2. Pancreatitis and gallbladder issues are possible with either. Tolerability is individual, and slow dose titration is the main way both manage side effects.
So Which Is Better?
On average, tirzepatide produces larger weight and glucose reductions, which is what the head-to-head and cross-trial data suggest. But "better" depends on the person: the right choice factors in the specific condition being treated, insurance coverage and cost, whether a pill is preferred, tolerability, and a clinician's judgment. Both are genuinely effective, and neither is a substitute for a conversation with a prescriber.
What Comes After Them
The next step beyond dual agonism is triple agonism. Retatrutide, an investigational drug targeting GIP, GLP-1 and glucagon, has posted even larger weight-loss figures in phase 3 trials — a sign of where this drug class is heading.
Frequently Asked Questions
Is tirzepatide better than semaglutide for weight loss?
On average, tirzepatide has produced larger weight loss in trials, and it beat semaglutide head-to-head on weight and A1c in SURPASS-2. Individual results vary, and both are effective.
What is the main difference between tirzepatide and semaglutide?
Tirzepatide activates two receptors (GIP and GLP-1); semaglutide activates only GLP-1. That extra receptor is the key difference.
Can you switch between them?
Switching is a medical decision made with a prescriber, based on response, tolerability, cost and availability. It is not something to do on your own.
Which has more delivery options?
Semaglutide — it comes as a weekly injection, a daily oral tablet (Rybelsus), and a newer oral pill for weight management. Tirzepatide is currently injection-only.
Disclaimer
This article is for educational and informational purposes only and is not medical advice. Tirzepatide and semaglutide are FDA-approved prescription medications that should be used only under the supervision of a licensed healthcare provider. The Peptide Library is an educational resource; consult your doctor before starting, stopping or changing any medication.